181 related articles for article (PubMed ID: 33914348)
1. Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: A U.S. cohort study.
Yousaf A; Tjien-Fooh FJ; Rentroia-Pacheco B; Quattrocchi E; Kobic A; Tempel D; Kolodney M; Meves A
Int J Dermatol; 2021 Jul; 60(7):851-856. PubMed ID: 33914348
[TBL] [Abstract][Full Text] [Related]
2. Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary.
Johansson I; Tempel D; Dwarkasing JT; Rentroia-Pacheco B; Mattsson J; Ny L; Olofsson Bagge R
Eur J Surg Oncol; 2022 Feb; 48(2):320-325. PubMed ID: 34794843
[TBL] [Abstract][Full Text] [Related]
3. Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.
Mulder EEAP; Dwarkasing JT; Tempel D; van der Spek A; Bosman L; Verver D; Mooyaart AL; van der Veldt AAM; Verhoef C; Nijsten TEC; Grunhagen DJ; Hollestein LM
Br J Dermatol; 2021 May; 184(5):944-951. PubMed ID: 32844403
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of the clinicopathologic and gene expression profile (CP-GEP) in patients with melanoma eligible for sentinel lymph node biopsy: A multicenter prospective Dutch study.
Stassen RC; Mulder EEAP; Mooyaart AL; Francken AB; van der Hage J; Aarts MJB; van der Veldt AAM; Verhoef C; Grünhagen DJ
Eur J Surg Oncol; 2023 Dec; 49(12):107249. PubMed ID: 37907016
[TBL] [Abstract][Full Text] [Related]
5. Utility of a Model for Predicting the Risk of Sentinel Lymph Node Metastasis in Patients With Cutaneous Melanoma.
Marchetti MA; Dusza SW; Bartlett EK
JAMA Dermatol; 2022 Jun; 158(6):680-683. PubMed ID: 35475908
[TBL] [Abstract][Full Text] [Related]
6. Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction.
Whitman ED; Koshenkov VP; Gastman BR; Lewis D; Hsueh EC; Pak H; Trezona TP; Davidson RS; McPhee M; Guenther JM; Toomey P; Smith FO; Beitsch PD; Lewis JM; Ward A; Young SE; Shah PK; Quick AP; Martin BJ; Zolochevska O; Covington KR; Monzon FA; Goldberg MS; Cook RW; Fleming MD; Hyams DM; Vetto JT
JCO Precis Oncol; 2021; 5():. PubMed ID: 34568719
[TBL] [Abstract][Full Text] [Related]
7. Cost evaluation of the Merlin assay for predicting melanoma sentinel lymph node biopsy metastasis.
Thao V; Dholakia R; Moriarty JP; Borah BJ; Dwarkasing J; Meves A
Int J Dermatol; 2023 Jan; 62(1):56-61. PubMed ID: 36440797
[TBL] [Abstract][Full Text] [Related]
8. Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).
Amaral T; Sinnberg T; Chatziioannou E; Niessner H; Leiter U; Keim U; Forschner A; Dwarkasing J; Tjien-Fooh F; Wever R; Flatz L; Eggermont A; Forchhammer S
Eur J Cancer; 2023 Mar; 182():155-162. PubMed ID: 36739215
[TBL] [Abstract][Full Text] [Related]
9. The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study.
Yamamoto M; Sickle-Santanello B; Beard T; Essner R; Martin B; Bailey CN; Guenther JM
Curr Med Res Opin; 2023 Mar; 39(3):417-423. PubMed ID: 36617959
[TBL] [Abstract][Full Text] [Related]
10. The Integrated i31-GEP Test Outperforms the MSKCC Nomogram at Predicting SLN Status in Melanoma Patients.
Tassavor M; Martin BJ; Glazer AM
Anticancer Res; 2023 Oct; 43(10):4511-4516. PubMed ID: 37772588
[TBL] [Abstract][Full Text] [Related]
11. CP-GEP (Merlin) gene expression profiling: can my melanoma patient forgo sentinel lymph node biopsy?
Quattrocchi E; Meves ES; Meves A
Ital J Dermatol Venerol; 2023 Aug; 158(4):292-301. PubMed ID: 37539500
[TBL] [Abstract][Full Text] [Related]
12. Should Sentinel Lymph Node Biopsy Be Performed for All T1b Melanomas in the New 8
Egger ME; Stevenson M; Bhutiani N; Jordan AC; Scoggins CR; Philips P; Martin RC; McMasters KM
J Am Coll Surg; 2019 Apr; 228(4):466-472. PubMed ID: 30660817
[TBL] [Abstract][Full Text] [Related]
13. Using the Merlin assay for reducing sentinel lymph node biopsy complications in melanoma: a retrospective cohort study.
Hieken TJ; Sadurnà MB; Quattrocchi E; Kobic A; Sominidi-Damodaran S; Dwarkasing JT; Meerstein-Kessel L; Bridges AG; Meves A
Int J Dermatol; 2022 Jul; 61(7):848-854. PubMed ID: 35100440
[TBL] [Abstract][Full Text] [Related]
14. Cervical sentinel lymph node biopsy for melanomas of the head and neck and upper thorax.
Wagner JD; Park HM; Coleman JJ; Love C; Hayes JT
Arch Otolaryngol Head Neck Surg; 2000 Mar; 126(3):313-21. PubMed ID: 10722003
[TBL] [Abstract][Full Text] [Related]
15. Association Between Patient Age and Lymph Node Positivity in Thin Melanoma.
Sinnamon AJ; Neuwirth MG; Yalamanchi P; Gimotty P; Elder DE; Xu X; Kelz RR; Roses RE; Chu EY; Ming ME; Fraker DL; Karakousis GC
JAMA Dermatol; 2017 Sep; 153(9):866-873. PubMed ID: 28724122
[TBL] [Abstract][Full Text] [Related]
16. Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma.
Yamamoto M; Fisher KJ; Wong JY; Koscso JM; Konstantinovic MA; Govsyeyev N; Messina JL; Sarnaik AA; Cruse CW; Gonzalez RJ; Sondak VK; Zager JS
Cancer; 2015 May; 121(10):1628-36. PubMed ID: 25677366
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy.
Gerami P; Cook RW; Russell MC; Wilkinson J; Amaria RN; Gonzalez R; Lyle S; Jackson GL; Greisinger AJ; Johnson CE; Oelschlager KM; Stone JF; Maetzold DJ; Ferris LK; Wayne JD; Cooper C; Obregon R; Delman KA; Lawson D
J Am Acad Dermatol; 2015 May; 72(5):780-5.e3. PubMed ID: 25748297
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma.
Gannon CJ; Rousseau DL; Ross MI; Johnson MM; Lee JE; Mansfield PF; Cormier JN; Prieto VG; Gershenwald JE
Cancer; 2006 Dec; 107(11):2647-52. PubMed ID: 17063497
[TBL] [Abstract][Full Text] [Related]
19. A Clinical Decision Tool to Calculate Pretest Probability of Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.
Tripathi R; Larson K; Fowler G; Han D; Vetto JT; Bordeaux JS; Yu WY
Ann Surg Oncol; 2023 Jul; 30(7):4321-4328. PubMed ID: 36840860
[TBL] [Abstract][Full Text] [Related]
20. Completion Lymph Node Dissection Based on Risk of Nonsentinel Metastasis in Cutaneous Melanoma of the Head and Neck.
Fritsch VA; Cunningham JE; Lentsch EJ
Otolaryngol Head Neck Surg; 2016 Jan; 154(1):94-103. PubMed ID: 26399717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]